Please select a Capability in order to start your service request.
Data To Be Presented on Improving Cleansing Compliance Through StartClean Cleansing ProgramJun 2, 2014
SAN DIEGO, June 2, 2014 /PRNewswire/ – At the 41st Annual Conference of the Association for Professionals in Infection Control and Epidemiology (APIC), CareFusion (NYSE:CFN), a leading global medical technology company, will launch three new products that are designed to help reduce surface contamination or the presence of microorganisms that can potentially cause infections during hospital stays and procedures.
The ChloraPrep® 1mL applicator is a new addition to the ChloraPrep line of preoperative skin preparation products. It provides clinicians with a unique applicator design and the same formulation they know and trust in a new 1 mL size. With its unique delivery system and winged activation design, the 1 mL applicator is easy to use and can help promote aseptic techniques and best practices. ChloraPrep skin prep products have been proven to be more effective than povidone-iodine at eliminating microorganisms on the skin that may cause infection.1,2,3
The ChloraShield® IV dressing with chlorhexidine gluconate (CHG) antimicrobial is a flexible and breathable dressing, that enhances patient care during vascular access procedures. The dressing features BeneHold™ CHG, an innovative adhesive technology from Vancive Medical Technologies™, an Avery Dennison business, which comfortably secures the dressing to the skin, absorbs fluid and protects the site from external contaminants. The CHG incorporated within the adhesive preserves the dressing from microbial growth. ChloraShield dressings are designed to be easy for clinicians to apply and remove, and comfortable for patients to wear. CareFusion is the exclusive distributor of the dressing in North America.
The MaxZero™ needleless connector from CareFusion is a new extension to a proprietary portfolio of needleless connectors and is designed to help improve patient safety and promote nursing best practices. With a solid, sealed surface, the connector provides a barrier to bacteria and contamination and enables effective three second disinfection with an alcohol pad. The design of the MaxZero needleless connector prevents reflux of blood into the catheter at disconnect and also has a smaller profile. A clear fluid path enhances flushing and anti-reflux technology prevents the need for a clamping sequence, helping save nurses time and reducing process steps.
In addition to new products, new data is being presented on tools that can improve patient compliance with physician cleansing instructions and how increased compliance can affect the amount of antiseptic present on the skin. A unique reminder system to improve bathing compliance is one of the key features to the StartClean Cleansing Program from CareFusion, where patients receive a 4 percent CHG cleanser with disposable sponges and an individualized service that contacts patients via text, email, or voice message reminding them to use the cleanser in accordance with physician instructions. The data will be presented by Dr. Charles Edmiston from the Medical College of Wisconsin during a poster presentation on Saturday, June 7 from 12:30 to 1:30 p.m.
Additional highlights in CareFusion booth #911 at the APIC conference include:
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.
1 Saltzman MD, Nuber GW, Gryzlo SM, Marecek GS, Koh JL. Efficacy of surgical preparation solutions in shoulder surgery. J Bone Joint Surg Am. 2009;91(8):1949–1953.
2 Ostrander RV, Botte MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87(5):980–985.
3 Adler MT, Brigger KR, Bishop KD, Mastrobattista JM. Comparison of bactericidal properties of alcohol-based chlorhexidine versus povidone-iodine prior to amniocentesis. Am J Perinatol. 2012;29(6):455–458. Epub 2012 Mar 7.
4 Surgical scrub comparison market research. Bernstein-Rein, 2010.
5 Denton GW. Chlorhexidine. In: Block SS. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:321-336.
6 Brown E, Wenzel RP, Hendley JO. Exploration of the microbial anatomy of normal human skin by using plasmid profiles of coagulase-negative staphylococci: search for the reservoir pf resident skin flora. J Infect Dis. 1989;160(4):644-650.
7 Centers for Disease Control and Prevention. Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings 2007. Available at: http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf.